Cargando…
Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
BACKGROUND: Lung cancer is the second most common cancer worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Patients with NSCLC have achieved great survival benefits from immunotherapies targeting immune checkpoints. Glucocorticoids (GCs) are frequently used for...
Autores principales: | Li, Nijiao, Zheng, Xuliang, Gan, Jinyan, Zhuo, Ting, Li, Xiaohong, Yang, Chuyi, Wu, Yanbin, Qin, Shouming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617908/ https://www.ncbi.nlm.nih.gov/pubmed/37925595 http://dx.doi.org/10.1097/CM9.0000000000002544 |
Ejemplares similares
-
Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Chen, Baoqing, et al.
Publicado: (2022) -
Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review
por: Kim, Bum Jun, et al.
Publicado: (2017) -
Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression
por: Huang, Hongyu, et al.
Publicado: (2022) -
Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017) -
How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Chen, Hua, et al.
Publicado: (2021)